Mouse Anti-COL1A2 Recombinant Antibody (003-02) (CBMAB-P0238-YC)

Mouse

Human, Dog

003-02

IgG1, κ

ELISA, IHC, IHC-P

Recombinant expressed PIIANP

Human, Dog

IgG1, κ

Monoclonal

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Store at 4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

Collagen Type I Alpha 2 Chain

COL1A2 is the pro-alpha2 chain of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIB, recessive Ehlers-Danlos syndrome Classical type, idiopathic osteoporosis, and atypical Marfan syndrome.

OI4

Type I collagen is a member of group I collagen (fibrillar forming collagen).

Blood coagulation Source: Reactome
Blood vessel development Source: UniProtKB
Bone mineralization Source: Ensembl
Cellular response to amino acid stimulus Source: Ensembl
Collagen fibril organization Source: UniProtKB
Collagen metabolic process Source: Ensembl
Cytokine-mediated signaling pathway Source: Reactome
Extracellular matrix assembly Source: Ensembl
Extracellular matrix organization Source: GO_Central
Leukocyte migration Source: Reactome
Odontogenesis Source: UniProtKB
Platelet activation Source: Reactome
Protein heterotrimerization Source: Ensembl
Regulation of blood pressure Source: UniProtKB
Regulation of immune response Source: Reactome
Rho protein signal transduction Source: UniProtKB
Skeletal system development Source: UniProtKB
Skin morphogenesis Source: UniProtKB
Transforming growth factor beta receptor signaling pathway Source: UniProtKB

Extracellular matrix

Ehlers-Danlos syndrome, arthrochalasia type, 2 (EDSARTH2):
A form of Ehlers-Danlos syndrome, a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDSARTH2 is an autosomal dominant condition characterized by frequent congenital hip dislocation and extreme joint laxity with recurrent joint subluxations and minimal skin involvement.
Osteogenesis imperfecta 1 (OI1):
An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI1 is a non-deforming form with normal height or mild short stature, and no dentinogenesis imperfecta.
Osteogenesis imperfecta 2 (OI2):
An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI2 is characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency.
Ehlers-Danlos syndrome, cardiac valvular type (EDSCV):
A form of Ehlers-Danlos syndrome, a group of connective tissue disorders characterized by skin hyperextensibility, articular hypermobility, and tissue fragility. EDSCV is an autosomal recessive disease characterized by mitral valve prolapse and insufficiency, mitral regurgitation, and aortic insufficiency, in addition to joint laxity, skin hyperextensibility and friability, and abnormal scar formation.
Osteogenesis imperfecta 3 (OI3):
An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI3 is characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera and dentinogenesis imperfecta.
Osteogenesis imperfecta 4 (OI4):
An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI4 is characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta.

Prolines at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains.